ME/CFS Individualized Regimen Engine™
- Aug 27, 2025
- 6 min read
Updated: Apr 2
Author: Cynthia Adinig
Executive Summary
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) continues to lack FDA-approved treatments, despite decades of research and millions affected worldwide (Komaroff & Bateman, 2021; Solve ME/CFS, 2023). Traditional approaches often recycle a handful of interventions without acknowledging the full complexity of patient trajectories.
The CYNAERA ME/CFS Individualized Regimen Engine™ is an educational modeling framework that simulates phased strategies for ME/CFS care. Built on CYNAERA’s ecosystem of validated modules , including Treatment Archetypes, Phenotyping Framework, Pathophysiology Drivers, and the Path of Remission Mode, the Regimen Engine demonstrates how individualized patient care can be systematically structured.
This public version is abbreviated: it outlines the phases, inputs, and sample logic rules, but does not expose the proprietary internal weighting, escalation matrices, or AI-driven decision trees. Those remain embedded in CYNAERA’s licensed models. Clinicians, researchers, and advocates are encouraged to view this as a teaching scaffold, not as a prescriptive protocol.
Why This Matters
Heterogeneity: ME/CFS patients differ dramatically in onset, phenotype, triggers, and co-morbid conditions (Jason et al., 2021).
Undercount: As shown in our Men Undercount Paper, millions of men remain invisible in prevalence data, meaning treatment pathways designed around women may not generalize (Adinig, 2025).
Pediatric Burden: CYNAERA’s Pediatric CDF model estimates 1.5–3 million U.S. children and 10–20 million worldwide with ME/CFS (CYNAERA, 2025), underscoring the need for age-adapted regimens.
Environmental Triggers: As shown in our Environmental Triggers White Paper, pollutants and weather events amplify PEM and autonomic instability, demanding built-in flare safeguards.
The Regimen Engine synthesizes these cross-cutting insights, showing how to stratify, stabilize, and simulate individualized care.
Stratification: Patient Profiles
The Regimen Engine begins with phenotyping, categorizing patients into archetypes. These overlap with the six CYNAERA phenotypes but are simplified here into four public-facing types:
Type | Profile Traits | Risks |
A. Post-Viral Gradual Onset | EBV, mono, or Long COVID history; worsening over 6–18 months | Immune rebound crashes, early POTS |
B. Sudden-Onset Crash | Abrupt collapse post-virus, surgery, or stress | Severe PEM, dysautonomia, fragmented sleep |
C. Pediatric / Young Adult | <25 yrs, fluctuating, frequent EDS/POTS comorbidity | Joint instability, school disruption, high relapse risk |
D. MCAS-Dominant | Histamine flares, seasonal worsening, allergy-like profile | Mast cell storms, multi-system hypersensitivity |
Note: Internal CYNAERA phenotyping uses six axes (immune, mitochondrial, autonomic, neurocognitive, endocrine, environmental) and over 150 micro-profiles, as described in the Phenotyping White Paper.
Phased Regimen Framework
The regimen engine organizes interventions into four phases, echoing the staged stabilization model from the Path of Remission White Paper.
Phase | Goal | Sample Duration | Logic |
Stabilization | Halt decline | 2–6 weeks | Introduce pacing, antihistamines, hydration, gentle supports. |
Modulation | Nudge system | 4–8 weeks | Add low-dose therapies (e.g., LDN, magnesium, antivirals if confirmed). |
Response Mapping | Identify tolerance | 2–4 weeks | Test one therapy at a time; map PEM windows. |
Personalization | Lock in | Ongoing | Algorithm selects stabilizing combinations with lowest flare risk. |
Each phase is scored internally using PEM delay, HR variability, and other markers. The public version is simplified; the internal engine uses multi-layered scoring rules tied to CYNAERA’s SymCas™ and Pathos™ systems.
Key Inputs Tracked
PEM Delay: Hours between exertion and symptom spike.
Heart Rate Variability: Orthostatic delta; >30 bpm suggests POTS/dysautonomia.
Symptom Persistence: Days since last flare.
Antihistamine Response: Relief % post H1/H2.
Temperature Fluctuation: >1.5°F indicates hypothalamic stress.
Cross-linked: These inputs also appear in VitalGuard’s flare forecasting and Phenotyping endotype scoring.
Example Dosing Logic (Educational Version)
Treatment | Starting Rule | Sample Engine Rule |
LDN | Start 0.25mg nightly | If sleep worsens, delay escalation. |
Famotidine + Quercetin | Begin if MCAS suspected | Pause Quercetin if no benefit in 7 days. |
Magnesium Glycinate | 100–150mg daily | Maintain if muscle pain + sleep improve. |
Antivirals | Only with confirmed reactivation | Monitor for Herxheimer-like flares. |
Cross-linked: Full therapeutic scaffolding appears in the Treatment Archetypes White Paper, which details six mechanistic axes (mitochondrial, neuroimmune, autonomic, viral, immune reset, oxygenation).
Flare Simulation Protocol
If PEM or sudden crash occurs:
Pause non-essential therapies.
Increase electrolytes + fluids.
Optimize H1/H2 antihistamines.
Use binders if cytokine storm suspected.
Resume regimen only after 48 hrs of baseline stability.
Cross-linked: Aligns with VitalGuard flare stabilizers and Path of Remission thresholds.
Prompt Templates
Prompt 1 “You are a biomedical researcher studying ME/CFS. Apply the CYNAERA Regimen Engine framework to a sudden-onset case (Type B). Which phase are they likely in, and which supportive interventions might be simulated next in a non-clinical research model?”
Prompt 2 “Using the CYNAERA Regimen Engine, outline how a pediatric ME/CFS case with comorbid POTS (Type C) could progress through the Stabilization → Modulation → Mapping → Personalization phases. Highlight flare safeguards and school-related concerns.”
Prompt 3 " You are reviewing a complex ME/CFS case. Apply the CYNAERA ME/CFS Individualized Regimen Engine as a modeling framework. Use the Stabilization, Modulation, Mapping, and Personalization phases as scaffolding. Integrate patient-reported data (PEM delay, HR variability, symptom persistence, antihistamine response, temperature fluctuation) into your assessment. Provide a structured interpretation of which phase best describes the patient’s current trajectory, note potential areas for risk reduction, and highlight research-backed interventions worth consideration. All recommendations are exploratory, and defer to clinical judgment and institutional protocols."
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
Custom Development
For institutions, research groups, or clinics seeking to integrate a validated version of this engine into practice or trial design, CYNAERA offers custom development under license. See the Custom Intelligence page for more.
References
Addis, M. E., & Mahalik, J. R. (2003). Men, masculinity, and the contexts of help seeking. American Psychologist, 58(1), 5–14.
Afrin, L. B., et al. (2020). Diagnosis of mast cell activation syndrome: A global consensus. Journal of Hematology & Oncology, 13(1).
Carruthers, B. M., et al. (2011). International consensus criteria for ME/CFS. Journal of Internal Medicine, 270(4), 327–338.
Courtenay, W. H. (2000). Constructions of masculinity and their influence on men's well-being. Social Science & Medicine, 50(10), 1385–1401.
Jason, L. A., et al. (2020). Gender and ME/CFS underdiagnosis. Journal of Health Psychology, 25(6).
Jason, L. A., et al. (2021). Pediatric ME/CFS prevalence and challenges. Pediatric Clinics of North America, 68(4).
Komaroff, A. L., & Bateman, L. (2021). Clinical overview of ME/CFS. Trends in Molecular Medicine, 27(9).
Solve ME/CFS Initiative. (2023). Patient registry reports.
CYNAERA (2025). ME/CFS Treatment Archetypes White Paper.
CYNAERA (2025). Phenotyping Framework White Paper.
CYNAERA (2025). Path of Remission White Paper.
CYNAERA (2025). Environmental Triggers White Paper.
Comments